Lilly to buy CoLucid for $960 mln to beef up migraine portfolio
January 18, 2017 at 06:58 AM EST
Jan 18 (Reuters) - Eli Lilly and Co said it would buy CoLucid Pharmaceuticals Inc for about $960 million to gain access to its experimental treatment for migraine.
